Stocktoria
Veradermics, Inc MANE
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2026-02-04
Chart by TradingView
2/9
Piotroski F — financial health
-13.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$72.3M | -$26.8M |
| Net income | -$70.0M | -$26.5M |
| Operating cash flow | -$71.6M | -$23.7M |
| Free cash flow | -$71.6M | -$23.7M |
| Total assets | $152.6M | $55.5M |
| Total liabilities | $9.2M | $4.7M |
| Shareholders' equity | -$121.0M | -$48.5M |
| Ratios | ||
| Return on assets | -45.9% | -47.7% |
| Return on equity | 57.8% | 54.6% |
| Current ratio | 16.66 | 11.77 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.54 (distress)
- Working capital / assets 0.939
- Retained earnings / assets -0.809
- EBIT / assets -0.474
- Equity / liabilities -13.217
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001827635 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.